We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
+26.22%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$246B
AUM Growth
+$40.4B
(+20%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-1.41%
Top 10 Holdings %
Top 10 Hldgs %
22.52%
Holding
3,466
New
266
Increased
1,402
Reduced
1,481
Closed
200
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$613M |
| 2 |
Match Group
MTCH
|
+$518M |
| 3 |
Meta Platforms (Facebook)
META
|
+$508M |
| 4 |
RTX Corp
RTX
|
+$456M |
| 5 |
Eli Lilly
LLY
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$828M |
| 2 |
Microsoft
MSFT
|
+$510M |
| 3 |
Gilead Sciences
GILD
|
+$465M |
| 4 |
Merck
MRK
|
+$376M |
| 5 |
Walmart Inc
WMT
|
+$369M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.64% |
| 2 | Healthcare | 14.1% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 12.19% |
| 5 | Communication Services | 9.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRNE
1876
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $5.18M | ﹤0.01% |
825,730
+312,194
| +61% | +$1.2M |
|
1877
Transocean
RIG
$5.82B
| $5.18M | ﹤0.01% |
2,831,245
+877,625
| +45% | +$1.36M |
|
|
HSKA
1878
DELISTED
Heska Corp
HSKA
| $5.18M | ﹤0.01% |
55,567
+3,673
| +7% | +$283K |
|
1879
SAP
SAP
$238B
| $5.17M | ﹤0.01% |
36,909
-65
| -0.2% | -$8.01K |
|
1880
Heritage Insurance Holdings
HRTG
$991M
| $5.16M | ﹤0.01% |
394,442
-3,088
| -0.8% | -$36.1K |
|
1881
AnaptysBio
ANAB
$1.68B
| $5.16M | ﹤0.01% |
231,143
+7,538
| +3% | +$138K |
|
1882
JELD-WEN Holding
JELD
$164M
| $5.16M | ﹤0.01% |
320,186
-12,075
| -4% | -$159K |
|
1883
Voyager Therapeutics
VYGR
$201M
| $5.14M | ﹤0.01% |
407,439
-7,310
| -2% | -$85K |
|
|
MFA
1884
MFA Financial
MFA
$933M
| $5.13M | ﹤0.01% |
514,998
+115,783
| +29% | +$896K |
|
1885
Replimune Group
REPL
$1.01B
| $5.13M | ﹤0.01% |
206,392
+40,871
| +25% | +$723K |
|
1886
Brookfield
BN
$108B
| $5.13M | ﹤0.01% |
291,187
-166,533
| -36% | -$2.93M |
|
|
AXNX
1887
DELISTED
Axonics, Inc. Common Stock
AXNX
| $5.11M | ﹤0.01% |
145,603
+14,979
| +11% | +$516K |
|
1888
Ryder
R
$10.1B
| $5.1M | ﹤0.01% |
135,977
+8,039
| +6% | +$267K |
|
1889
Urban Outfitters
URBN
$6.59B
| $5.08M | ﹤0.01% |
333,675
+164,910
| +98% | +$2.83M |
|
1890
Sanofi
SNY
$104B
| $5.07M | ﹤0.01% |
99,378
-166,591
| -63% | -$8.1M |
|
1891
Universal Electronics
UEIC
$61.3M
| $5.06M | ﹤0.01% |
108,117
-41,727
| -28% | -$1.76M |
|
1892
AAR Corp
AIR
$5.76B
| $5.05M | ﹤0.01% |
244,560
-20,224
| -8% | -$392K |
|
|
VSTO
1893
DELISTED
Vista Outdoor Inc.
VSTO
| $5.05M | ﹤0.01% |
349,711
-123,805
| -26% | -$1.24M |
|
1894
Collegium Pharmaceutical
COLL
$956M
| $5.05M | ﹤0.01% |
288,557
+11,509
| +4% | +$225K |
|
|
DCH
1895
Dauch Corp
DCH
$1.51B
| $5.03M | ﹤0.01% |
662,363
-244,990
| -27% | -$1.41M |
|
|
UCTT
1896
Ultra Clean Holdings
UCTT
$3.95B
| $5.03M | ﹤0.01% |
222,186
+8,743
| +4% | +$166K |
|
1897
CRA International
CRAI
$1.06B
| $5.02M | ﹤0.01% |
127,009
-32,361
| -20% | -$1.23M |
|
1898
Tidewater
TDW
$4.12B
| $5.01M | ﹤0.01% |
896,832
+72,223
| +9% | +$410K |
|
|
FLXN
1899
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $4.99M | ﹤0.01% |
379,602
-12,385
| -3% | -$128K |
|
|
ICPT
1900
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $4.99M | ﹤0.01% |
104,045
-938
| -0.9% | -$72.5K |
|
Similar funds
VFT
Nuveen's Q2 2020 Portfolio in Review
As of Q2 2020, Nuveen held 3,466 positions worth $246B, up 20% from $205B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Nuveen's Q2 2020 filing shows 266 new, 1,402 increased, 1,481 reduced and 200 closed positions. Its largest new stake was Zoom: 841,153 shares worth $213M. The largest sale was Amazon, an estimated $828M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q2 2020 buy was Zoom: 841,153 shares worth $213M.
- Nuveen added most to AbbVie in Q2 2020, an estimated $613M increase.
- Nuveen's biggest Q2 2020 reduction was Amazon, cutting an estimated $828M.
- Nuveen fully exited Allergan plc in Q2 2020, selling an estimated $212M.
- Nuveen's ten largest holdings make up 23% of its $246B portfolio in Q2 2020.
- Nuveen opened 266 new positions and closed 200 in Q2 2020.
- Nuveen's portfolio value rose 20% quarter-over-quarter to $246B.
Based on Nuveen's 13F filing for Q2 2020, filed 14 Aug 2020.